PSTI
Income statement / Annual
Last year (2021), Pluristem Therapeutics Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2021, Pluristem Therapeutics Inc.'s net income was -$49.87 M.
See Pluristem Therapeutics Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
| Period Ended |
06/30/2021 |
06/30/2020 |
06/30/2019 |
06/30/2018 |
06/30/2017 |
06/30/2016 |
06/30/2015 |
06/30/2014 |
06/30/2013 |
06/30/2012 |
| Operating Revenue |
$0.00
|
$23,000.00
|
$54,000.00
|
$50,000.00
|
$0.00
|
$2.85 M
|
$379,000.00
|
$379,000.00
|
$679,000.00
|
$716,000.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$2,000.00 |
$2,000.00 |
$0.00 |
$100,000.00 |
$13,000.00 |
$11,000.00 |
$20,000.00 |
$0.00 |
| Gross Profit |
$0.00 |
$23,000.00 |
$52,000.00 |
$48,000.00 |
$0.00 |
$2.75 M |
$366,000.00 |
$368,000.00 |
$659,000.00 |
$716,000.00 |
| Gross Profit Ratio |
0 |
1 |
0.96 |
0.96 |
0 |
0.96 |
0.97 |
0.97 |
0.97 |
1 |
| Research and Development
Expenses |
$30.07 M
|
$21.58 M
|
$26.43 M
|
$22.63 M
|
$21.09 M
|
$19.58 M
|
$19.17 M
|
$19.54 M
|
$17.23 M
|
$9.18 M
|
| General & Administrative
Expenses |
$20.56 M
|
$7.92 M
|
$9.16 M
|
$11.19 M
|
$6.93 M
|
$6.49 M
|
$6.46 M
|
$8.68 M
|
$5.65 M
|
$0.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$20.56 M
|
$7.92 M
|
$9.16 M
|
$11.19 M
|
$6.93 M
|
$6.49 M
|
$6.46 M
|
$8.68 M
|
$5.65 M
|
$6.57 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
-$43,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$50.62 M |
$29.50 M |
$35.58 M |
$33.78 M |
$28.02 M |
$26.07 M |
$25.63 M |
$28.22 M |
$22.88 M |
$15.75 M |
| Cost And Expenses |
$50.62 M |
$29.50 M |
$35.59 M |
$33.78 M |
$28.02 M |
$26.17 M |
$25.65 M |
$28.23 M |
$22.90 M |
$15.75 M |
| Interest Income |
$492,000.00 |
$384,000.00 |
$385,000.00 |
$276,000.00 |
$122,000.00 |
$149,000.00 |
$112,000.00 |
$246,000.00 |
$266,000.00 |
$575,000.00 |
| Interest Expense |
$78,000.00 |
$196,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$29,000.00 |
$12,000.00 |
| Depreciation &
Amortization |
$1.37 M
|
$1.57 M
|
$1.96 M
|
$2.02 M
|
$2.18 M
|
$2.15 M
|
$2.07 M
|
$1.90 M
|
$1.03 M
|
$435,000.00
|
| EBITDA |
-$48.42 M
|
-$27.39 M
|
-$33.35 M
|
-$24.11 M
|
-$25.64 M
|
-$21.10 M
|
-$22.60 M
|
-$25.03 M
|
-$20.09 M
|
-$14.35 M
|
| EBITDA Ratio |
0 |
-1190.7 |
-617.5 |
-482.16 |
0 |
-7.41 |
-59.64 |
-66.04 |
-29.59 |
-20.04 |
| Operating Income Ratio
|
0
|
-1281.57
|
-658
|
-674.62
|
0
|
-8.19
|
-66.67
|
-73.48
|
-32.73
|
-20.99
|
| Total Other
Income/Expenses Net |
$758,000.00
|
$324,000.00
|
$225,000.00
|
$7.61 M
|
$205,000.00
|
$73,000.00
|
$590,000.00
|
$918,000.00
|
$1.07 M
|
$237,000.00
|
| Income Before Tax |
-$49.87 M |
-$29.15 M |
-$35.31 M |
-$26.13 M |
-$27.81 M |
-$23.25 M |
-$24.68 M |
-$26.93 M |
-$21.16 M |
-$14.79 M |
| Income Before Tax Ratio
|
0
|
-1267.48
|
-653.83
|
-522.52
|
0
|
-8.17
|
-65.11
|
-71.06
|
-31.16
|
-20.66
|
| Income Tax Expense |
$836,000.00 |
$520,000.00 |
$225,000.00 |
$7.61 M |
$205,000.00 |
$73,000.00 |
$590,000.00 |
$918,000.00 |
$1.10 M |
$249,000.00 |
| Net Income |
-$49.87 M |
-$29.15 M |
-$35.31 M |
-$26.13 M |
-$27.81 M |
-$23.25 M |
-$24.68 M |
-$26.93 M |
-$21.16 M |
-$14.79 M |
| Net Income Ratio |
0 |
-1267.48 |
-653.83 |
-522.52 |
0 |
-8.17 |
-65.11 |
-71.06 |
-31.16 |
-20.66 |
| EPS |
-1.77 |
-1.6 |
-2.86 |
-2.47 |
-3.18 |
-2.92 |
-3.51 |
-4.24 |
-3.81 |
-3.36 |
| EPS Diluted |
-1.77 |
-1.6 |
-2.86 |
-2.47 |
-3.18 |
-2.92 |
-3.51 |
-4.24 |
-3.81 |
-3.36 |
| Weighted Average Shares
Out |
$28.11 M
|
$18.20 M
|
$12.33 M
|
$10.59 M
|
$8.74 M
|
$7.95 M
|
$7.03 M
|
$6.35 M
|
$5.55 M
|
$4.40 M
|
| Weighted Average Shares
Out Diluted |
$28.11 M
|
$18.20 M
|
$12.33 M
|
$10.59 M
|
$8.74 M
|
$7.95 M
|
$7.03 M
|
$6.35 M
|
$5.55 M
|
$4.40 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
